Dairy producers and veterinarians now have another tool in the prevention and reduction in antibiotic use with the debut of the first vaccine licensed for dairy cattle to prevent mastitis caused by Klebsiella pneumoniae. AgriLabs announced on July 23 that KLEBVax SRP was now available on the market.
A similar autogenous product was offered by AgriLabs in partnership with Epitopix that used a bacterial extract of Klebsiella SRP.
“Klebsiella is a widespread pathogen that has been difficult to prevent in dairy operations and has cost producers significant losses,” says Sean O’Hare, executive vice president for AgriLabs. “We are excited to offer KLEBVax SRP to veterinarians and dairy producers as a new management tool to reduce the incidence of Klebsiella mastitis. As a vaccine, KLEBVax SRP will provide an alternative to antibiotics and help shift the focus from treatment to prevention.”
A field study by Iowa State University using KLEBVax SRP showed a 71% reduction in infection within 90 days of calving versus a placebo group.
Other benefits included:
- 42% reduction in somatic cell count
- 2 lbs in increased milk production, per cow/per day
The new vaccine works by activating the animal’s immune system to produce antibodies that bind and block the transfer of iron through bacterial cell wall porins. Gram-negative bacteria such as Klebsiella require iron for growth and survival, so the vaccine helps deprive the bacteria of nutrients.
“The unique process of the SRP technology makes it well-suited for the challenges associated with disease-causing bacteria such as Klebsiella,” says Jim Sandstrom, DVM, managing director of Epitopix, LLC. “With several years of field experience with autogenous Klebsiella SRP vaccines, we are confident the new KLEBVax SRP product will help dairy veterinarians and producers manage mastitis infections caused by Klebsiella.”